参考文献/References:
[1] 王增武,刘静,李建军,等. 中国血脂管理指南（2023年）[J]. 中国循环杂志,2023,38(3):237-271.
[2] 中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志,2023,38(6):583-612.
[3] Ference BA,Ginsberg HN,Graham I,et al. Low-density lipoproteins cause atherosclerotic
cardiovascular disease. 1. Evidence from genetic,epidemiologic,and clinical studies. A
consensus statement from the European Atherosclerosis Society Consensus Panel[J]. Eur
Heart J,2017,38(32):2459-2472.
[4] Baigent C,Blackwell L,Emberson J,et al. Efficacy and safety of more intensive lowering ofLDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomised trials[J]. Lancet,2010,376(9753):1670-1681.
[5] Bonovas S,Nikolopoulos G,Sitaras NM. Efficacy and safety of more intensive lowering ofLDL cholesterol[J]. Lancet,2011,377(9767):715-716.
[6] 李永林,司春婴,顾问,等. PCSK9抑制剂和Inclisiran在动脉粥样硬化中的研究进展[J]. 医学研究生学报,2021,34(4):439-443.
[7] 谢坤,李勇. 高甘油三酯血症临床管理多学科专家共识[J]. 中国循环杂志,2023,38(6):621-633.
[8] Cannon CP,Blazing MA,Giugliano RP,et al. Ezetimibe added to statin therapy after acute
coronary syndromes[J]. N Engl J Med,2015,372(25):2387-2397.
[9] 侯立强,孙燕,任雷,等. 新型siRNA药物：inclisiran在降脂治疗中的研究进展[J]. 中国医药导刊,2023,25(2):140-145.
[10] Gallego-Colon E,Daum A,Yosefy C. Statins and PCSK9 inhibitors:a new lipid-lowering
therapy[J]. Eur J Pharmacol,2020,878:173114.
[11] Shadid M,Badawi M,Abulrob A. Antisense oligonucleotides:absorption,distribution,metabolism,and excretion[J]. Expert Opin Drug Metab Toxicol,2021,17(11):1281-1292.
[12] Shen X,Corey DR. Chemistry,mechanism and clinical status of antisense oligonucleotides
and duplex RNAs[J]. Nucleic Acids Res,2018,46(4):1584-1600.
[13] Khvorova A. Oligonucleotide therapeutics—A new class of cholesterol-lowering drugs[J].
N Engl J Med,2017,376(1):4-7.
[14] Brown CR,Gupta S,Qin J,et al. Investigating the pharmacodynamic durability of
GalNAc-siRNA conjugates[J]. Nucleic Acids Res,2020,48(21):11827-11844.
[15] Bogaert B,Sauvage F,Guagliardo R,et al. A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs[J]. J Control Release,2022,350:256-270.
[16] Crooke ST,Witztum JL,Bennett CF,et al. RNA-targeted therapeutics[J]. Cell Metab,2018,27(4):714-739.
[17] Lu Y,Huang W,Li M,et al. Exosome-based carrier for RNA delivery:progress and
challenges[J]. Pharmaceutics,2023,15(2):598
[18] Henney NC,Banach M,Penson PE. RNA silencing in the management of dyslipidemias[J].
Curr Atheroscler Rep,2021,23(11):69.
[19] Weng Y,Xiao H,Zhang J,et al. RNAi therapeutic and its innovative biotechnological
evolution[J]. Biotechnol Adv,2019,37(5):801-825.
[20] 赵紫楠,史琛,胡欣,等. 小干扰RNA降脂药物药学专家共识[J]. 中国医院药学杂志,2024,44(1):9-17.
[21] 张磊,智昱,刘丽,等. 新型小干扰RNA降脂药物Inclisiran研究进展[J]. 中国心血管杂志,2022,27(2):176-178.
[22] Ray KK,Wright RS,Kallend D,et al. Two phase 3 trials of inclisiran in patients with
elevated LDL cholesterol[J]. N Engl J Med,2020,382(16):1507-1519.
[23] Wright RS,Ray KK,Raal FJ,et al. Pooled patient-level analysis of inclisiran trials in
patients with familial hypercholesterolemia or atherosclerosis[J]. J Am Coll Cardiol,2021,77(9):1182-1193.
[24] Ray KK,Raal FJ,Kallend DG,et al. Inclisiran and cardiovascular events:a patient-level
analysis of phase Ⅲ trials[J]. Eur Heart J,2023,44(2):129-138.
[25] Cordero A,Santos-Gallego CG,Facila L,et al. Estimation of the major cardiovascular event
prevention with Inclisiran[J]. Atherosclerosis,2020,313:76-80.
[26] Kosmas CE,Munoz EA,Skavdis A,et al. Inclisiran for the treatment of cardiovascular
disease:a short review on the emerging data and therapeutic potential[J]. Ther Clin Risk
Manag,2020,16:1031-1037.
[27] Khan SA,Naz A,Qamar MM,et al. Meta-analysis of inclisiran for the treatment of
hypercholesterolemia[J]. Am J Cardiol,2020,134:69-73.
[28] Ray KK,Stoekenbroek RM,Kallend D,et al. Effect of 1 or 2 doses of inclisiran on
low-density lipoprotein cholesterol levels:one-year follow-up of the ORION-1 r andomized
clinical t rial[J]. JAMA Cardiol,2019,4(11):1067-1075.
[29] Raal FJ,Kallend D,Ray KK,et al. Inclisiran for the treatment of heterozygous familial
hypercholesterolemia[J]. N Engl J Med,2020,382(16):1520-1530.
[30] Raal F,Durst R,Bi R,et al. Efficacy,safety,and tolerability of inclisiran in patients with
homozygous familial hypercholesterolemia:results from the ORION-5 randomized clinical
trial[J]. Circulation,2024,149(5):354-362
[31] Norata GD,Tibolla G,Catapano AL. Targeting PCSK9 for hypercholesterolemia[J]. Annu
Rev Pharmacol Toxicol,2014,54:273-293.
[32] Lagace TA,Curtis DE,Garuti R,et al. Secreted PCSK9 decreases the number of LDL
receptors in hepatocytes and in livers of parabiotic mice[J]. J Clin Invest,2006,116(11):2995-3005.
[33] Huynh K. Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab[J]. Nat Rev Cardiol,2015,12(5):261.
[34] Mulder J,Galema-Boers A,Roeters VLJ. First clinical experiences with inclisiran in a
real-world setting[J]. J Clin Lipidol,2023,17(6):818-827.
[35] Cunningham D,Danley DE,Geoghegan KF,et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia[J]. Nat Struct Mol Biol,2007,14(5):413-419.
[36] Kallend D,Stoekenbroek R,He Y,et al. Pharmacokinetics and pharmacodynamics of
inclisiran,a small interfering RNA therapy,in patients with hepatic impairment[J]. J Clin
Lipidol,2022,16(2):208-219.
[37] Wright RS,Collins MG,Stoekenbroek RM,et al. Effects of renal impairment on the
pharmacokinetics,efficacy,and safety of inclisiran:an analysis of the ORION-7 and
ORION-1 studies[J]. Mayo Clin Proc,2020,95(1):77-89.
[38] Boren J,Chapman MJ,Krauss RM,et al. Low-density lipoproteins cause atherosclerotic
cardiovascular disease:pathophysiological,genetic,and therapeutic insights:a consensus
statement from the European Atherosclerosis Society Consensus Panel[J]. Eur Heart J,2020,41(24):2313-2330.
[39] O’Donoghue ML,Rosenson RS,Gencer B,et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease[J]. N Engl J Med,2022,387(20):1855-1864.
[40] O’Donoghue ML,Rosenson RS,Gencer B,等. Olpasiran治疗动脉粥样硬化性心血管疾病患者的临床研究[J]. 中国临床药理学杂志,2023,39(4):482.
[41] Ginsberg HN,Goldberg IJ. Broadening the scope of dyslipidemia therapy by targeting
APOC3 (apolipoprotein C3) and ANGPTL3(angiopoietin-like protein 3)[J]. Arterioscler
Thromb Vasc Biol,2023,43(3):388-398.
[42] Mercep I,Strikic D,Sliskovic AM,et al. New therapeutic approaches in treatment of
dyslipidaemia—A narrative review[J]. Pharmaceuticals(Basel) ,2022,15(7):839.
[43] Lamb YN. Correction to:inclisiran:first approval[J]. Drugs,2021,81(9):1129.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(6):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]李乐亮,综述,李萍,等.炎症标志物与颈动脉粥样斑块的稳定性[J].心血管病学进展,2016,(3):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
LI Leliang,LI Ping.Stability of Inflammatory Markers and Carotid Artery Plaque[J].Advances in Cardiovascular Diseases,2016,(6):219.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.001]
[3]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[4]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[5]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(6):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[6]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[7]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[8]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[9]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[10]武亚琳,梁斌,杨志明.NLRP3/IL-1β途径的促动脉粥样硬化作用及临床应用[J].心血管病学进展,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
WU Yalin,LIANG Bin,YANG Zhiming.The Role of NLRP3/IL-1in Atherosclerosis and Clinical Application[J].Advances in Cardiovascular Diseases,2019,(6):943.[doi:10.16806/j.cnki.issn.1004-3934.2016.06.026]
[11]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(6):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[12]邹先明 赵然尊.长链非编码RNA ANRIL与心血管疾病的研究进展[J].心血管病学进展,2020,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
ZOU Xianming,ZHAO Ranzun.Long Non-Coding RNA ANRIL and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(6):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[13]毕一鸣 曹丰.内皮细胞功能异常与动脉粥样硬化的研究进展[J].心血管病学进展,2022,(2):150.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.014]
BI YimingCAO Feng.Vascular Endothelial Cells Involved?n the Pathophysiological Process of Atherosclerosis[J].Advances in Cardiovascular Diseases,2022,(6):150.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.014]
[14]董博华 吴雨晴 扈家源 魏宇涵 张桂彬 赵亚楠 陈喆 杨文琦.细颗粒物暴露对急性冠脉综合征作用机制的研究进展[J].心血管病学进展,2023,(2):132.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.008]
DONG Bohua,WU Yuqing,HU Jiayuan,et al.Research Progress on the Mechanism of PM2.5 Exposure on Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2023,(6):132.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.008]
[15]刘张弛 杨波.瞬时受体电位香草酸亚型4在心血管疾病中的研究进展[J].心血管病学进展,2023,(9):777.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.000]
LIU Zhangchi,YANG Bo?/html>.Transient Receptor Potential Vanilloid 4 in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(6):777.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.000]
[16]龙雪蛟 洪绍彩 贝俊杰.血小板参数在心血管疾病中的研究进展[J].心血管病学进展,2023,(10):945.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.018]
LONG Xuejiao,HONG Shaocai,BEI Junjie.Progress of Platelet Parameters in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2023,(6):945.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.018]
[17]黄佳宇 熊安琪 蒋弼瀛 陈文佳.液-液相分离在心血管疾病中的研究进展[J].心血管病学进展,2024,(7):603.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.007]
HUANG Jiayu,XIONG Anqi,JIANG Biying,et al.Liquid-Liquid Phase Separation in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2024,(6):603.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.007]